These results, along with the fact that the JAK inhibitor tofacitinib significantly reduced signs and symptoms of RA and inhibited the progression of structural joint damage, as compared with methotrexate (30), suggest the possibility of IL-7 as a therapeutic target, inhibiting IL-7-induced bone loss. This evidence concerns the gene IL7 and rheumatoid arthritis.